专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明专利

AU2020204267A1 Compositions and methods for immune cell modulation in adoptive immunotherapies 未知
公开(公告)号：AU2020204267A1
公开(公告)日：2020-07-16
申请号：AU2020204267
申请日：2020-06-26
申请人： FATE THERAPEUTICS INC
发明人： ROSEN JONATHAN , REZNER BETSY , VALAMEHR BAHRAM , BJORDAHL RYAN , PERALTA EIGEN
IPC分类号： C12N5/0783 , A61K35/17
摘要： Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

92. 发明专利

SG11202004833SA IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS 未知
公开(公告)号：SG11202004833SA
公开(公告)日：2020-06-29
申请号：SG11202004833S
申请日：2018-11-30
申请人： FATE THERAPEUTICS INC
发明人： VALAMEHR BAHRAM , BJORDAHL RYAN , LEE TOM , GAIDAROVA SVETLANA
IPC分类号： C12N5/074 , A61K35/17 , A61K35/545 , A61K39/395 , C07K14/735 , C12N5/078 , C12N5/0783
摘要： Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

93. 发明专利

SG11202002625YA CELLULAR REPROGRAMMING USING TEMPORAL AND TRANSIENT PLASMID VECTOR EXPRESSION SYSTEM 未知
公开(公告)号：SG11202002625YA
公开(公告)日：2020-04-29
申请号：SG11202002625Y
申请日：2018-10-10
申请人： FATE THERAPEUTICS INC
发明人： VALAMEHR BAHRAM , ROBINSON MEGAN
IPC分类号： C12N5/074 , C07K14/005 , C07K14/47
摘要： Provided are methods and compositions for inducing the reprogramming of a non-pluripotent to an iPSC having desirable properties using a vector system providing transient and temporal expression of transgenes that are short-lived. Also provided are reprogramming cells and iPSC populations or clonal cell lines using the provided reprogramming methods and compositions. Further provided are genome-engineered iPSCs and derived cells redifferentiated therefrom to comprise targeted editing involving insertions and deletions in one or more selected genomic loci.

94. 发明专利

AU2018283041A1 Compositions and methods for inducing myeloid suppressive cells and use thereof 未知
公开(公告)号：AU2018283041A1
公开(公告)日：2020-01-30
申请号：AU2018283041
申请日：2018-06-13
申请人： FATE THERAPEUTICS INC
发明人： PARONE PHILIPPE A , TACKE ROBERT S , VALAMEHR BAHRAM , SHOEMAKER DANIEL , HOSKING MARTIN , GUERRETTAZ LISA
IPC分类号： C12N5/078 , A61K35/15
摘要： Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potential in treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.

95. 发明专利

CA3078734A1 CELLULAR REPROGRAMMING USING TEMPORAL AND TRANSIENT PLASMID VECTOR EXPRESSION SYSTEM 未知
公开(公告)号：CA3078734A1
公开(公告)日：2019-04-18
申请号：CA3078734
申请日：2018-10-10
申请人： FATE THERAPEUTICS INC
发明人： VALAMEHR BAHRAM , ROBINSON MEGAN
IPC分类号： C12N15/85 , A61K31/506 , A61K35/12 , A61K35/545 , C07K14/05 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/63
摘要： Provided are methods and compositions for inducing the reprogramming of a non-pluripotent to an iPSC having desirable properties using a vector system providing transient and temporal expression of transgenes that are short-lived. Also provided are reprogramming cells and iPSC populations or clonal cell lines using the provided reprogramming methods and compositions. Further provided are genome-engineered iPSCs and derived cells redifferentiated therefrom to comprise targeted editing involving insertions and deletions in one or more selected genomic loci.

96. 发明专利

SG11201803144WA GENOMIC ENGINEERING OF PLURIPOTENT CELLS 未知
公开(公告)号：SG11201803144WA
公开(公告)日：2018-05-30
申请号：SG11201803144W
申请日：2016-11-04
申请人： FATE THERAPEUTICS INC
发明人： VALAMEHR BAHRAM , ABUJAROUR RAMZEY , LEE TOM TONG , LAN WEIJIE , CLARKE RAEDUN , BJORDAHL RYAN
IPC分类号： C12N15/85 , C12N5/074
摘要： Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

97. 发明专利

ES2654994T3 Terapia mejorada con células madre y precursoras hematopoyéticas 未知
公开(公告)号：ES2654994T3
公开(公告)日：2018-02-15
申请号：ES11817137
申请日：2011-08-12
申请人： FATE THERAPEUTICS INC
发明人： SHOEMAKER DANIEL , MULTANI PRATIK , DESPONTS CAROLINE , ROBBINS DAVID , GRAYSON PAUL , MENDLEIN JOHN
IPC分类号： A61K35/12 , C12N5/0789 , A61K35/28
摘要： Una composición terapéutica que comprende una población de células que comprende al menos un millón de células madre o precursoras hematopoyéticas humanas en la que: a) las células madre o precursoras hematopoyéticas se pusieron en contacto ex vivo a una temperatura de 33 ºC a 41 ºC con un agente que aumenta la expresión genética de CXCR4 en las células, en la que el agente es un potenciador de AMPc, un activador de Gα-s, un agente que se une de forma selectiva al receptor PGE2EP4, o que comprende PGE2 o un agonista de PGE2R2 o PGE2R4 b) la expresión genética de CXCR4 aumenta en las células madre o precursoras hematopoyéticas al menos veces en comparación con la expresión de CXCR4 en células madre o precursoras hematopoyéticas no puestas en contacto; y c) en la que la composición terapéutica comprende una cantidad terapéuticamente eficaz, estéril, de células madre o precursoras hematopoyéticas preparada para su administración a un paciente, en la que las células madre o precursoras hematopoyéticas se pusieron en contacto opcionalmente con el agente durante un periodo de tiempo de: [[a]]1) al menos una hora; [[b]]2) de una hora a seis horas; [[c]]3) de dos horas a seis horas; o [[d]]4) dos horas.

98. 发明专利

AU2017203597A1 Impoved hematopoietic stem and progenitor cell therapy 未知
公开(公告)号：AU2017203597A1
公开(公告)日：2017-06-15
申请号：AU2017203597
申请日：2017-05-29
申请人： FATE THERAPEUTICS INC
发明人： SHOEMAKER DANIEL , MULTANI PRATIK , DESPONTS CAROLINE , ROBBINS DAVID L , GRAYSON PAUL , MENDLEIN JOHN
IPC分类号： A61K35/12 , A61K35/44 , A61K38/17 , A61P35/00
摘要： The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of modified hematopoietic stem and/or progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic composition. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

99. 发明专利

AU2012321088B8 Enhanced stem cell composition 未知
公开(公告)号：AU2012321088B8
公开(公告)日：2016-12-15
申请号：AU2012321088
申请日：2012-11-29
申请人： FATE THERAPEUTICS INC
发明人： DESPONTS CAROLINE , SHOEMAKER DAN , ROBBINS DAVID , MENDLEIN JOHN D
IPC分类号： A61K35/12 , A61K35/51
摘要： H:\amtJlnav

100. 发明专利

AU2012321088A8 Enhanced stem cell composition 未知
公开(公告)号：AU2012321088A8
公开(公告)日：2016-12-15
申请号：AU2012321088
申请日：2012-11-29
申请人： FATE THERAPEUTICS INC
发明人： SHOEMAKER DAN , ROBBINS DAVID , MENDLEIN JOHN D , DESPONTS CAROLINE
IPC分类号： A61K35/12 , A61K35/51
摘要： The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution. " C""121 a l-- --- -- --- --- --- -- -- -- - -- -- - -- - -- -- - -- - -- -- - -- - -- -- - - -- -- - -- - -- -- - -- - -- -- - -- - -- -- - -- - -- -- --- - -- -- - -- -- ---- ---- - -- ---- ----- - - -- - -- - -- - -- - - - -- -- - -- - -- -- - - - --- - -I- - - -- -- - - - -- - - -- - - - -- --- -- - - - onx 1 ' 13 'Y'8o ' clyz'-11~ ' Uo (l~c t' *""c acok"c:azl dCfly .s'iid zi -- -- ---- ----- --- ---- ------ --- ---- --- ---- --- ---- --- ------ ---- --- ---- --- ---- --- --- --- ---- --- ---- --- ---- --- ---- - -- ---- ---- ---- ---- ---- --------- ss-- -- ------- ------ ------ ---- --- ----- ------s l- ---- --v-- ------- ------ ---- 2647224 vl/ST

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式